19.04.2011 • NewsAlbert von HebelAltanaBYK

Albert von Hebel Appointed Member of the Management Team of BYK-Chemistry

Albert von Hebel is BYK-Chemistrys new managing director since April 1
Albert von Hebel is BYK-Chemistry's new managing director since April 1

With effect from April 1, Albert von Hebel succeeds Gerd Büscher as Managing Director at Byk-Chemistry, a subsidiary of Altana. In his new role, he is responsible for the areas of finance, controlling, purchasing, IT, integrated management systems, and general administration.

Albert von Hebel is 49 years of age and was born in Papenburg, Emsland in Lower Saxony. After studying business economics in Münster, he worked for roughly eight years at an auditing and tax advisory company in Düsseldorf. During this time, he successfully completed his tax consultant state examination. In the following  20 years, he was employed in a variety of roles in commercial departments of the companies within the Altana Group. In 1996 he moved to BYK-Chemistry in Wesel. For the last four years, Albert von Hebel has been Head of Finance & Controlling of Altana.

Mr Büscher is retiring in May - after 20 years' service with the company.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.